Courtesy of Benzinga.
TauTona Group, a medical device incubator and investment fund focused on the rapid development of innovative medical products, today announced that its wholly-owned subsidiary Aline Aesthetics has completed the sale of its Aline hyaluronic acid (HA) thread technology to Allergan, Inc. The Aline HA technology is under development for use as a dermal filler.
“We are delighted to announce the sale of our third product, Aline HA, to Allergan,” said Geoffrey Gurtner M.D., managing partner at TauTona and professor of plastic surgery at Stanford University.
Aline HA is comprised of a solid state, cross-linked hyaluronic acid in thread form that is attached to a needle.
“We are very pleased to announce TauTona’s third exit in recent months,” said Dr. Gurtner. “At TauTona we are pursuing a new venture capital model: one that develops the insights of physicians and inventors using a capital efficient process to turn them into commercial products. Our third exit provides an excellent multiple on the invested capital and, in combination with our other exits, will contribute to a strong return for our first fund.”
Posted-In: News Asset Sales Press Releases
